 |
submitted by /u/mvea [link] [comments] |
Seaweed-derived drug therapeutically remodels gut microbiome and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression in a mouse model. The drug is undergoing Phase 3 human clinical trials and has just been approved to treat Alzheimer’s in China.
Seaweed-derived drug therapeutically remodels gut microbiome and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression in a mouse model. The drug is undergoing Phase 3 human clinical trials and has just been approved to treat Alzheimer’s in China.
https://ift.tt/2WWnxVT November 06, 2019 at 06:39AM https://ift.tt/1R552o9
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment